Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
Analysis of 4 cohorts (UK,Spain,Germany,Denmark,n =251,719) found reduction in bleeding risk for DOACs doesn’t resemble reductions found in trials. This could be at least partially attributable to nonadherence and limited external validity of trials, reflecting real‐life settings
Source:
British Journal of Clinical Pharmacology